Radiological evaluation of newly diagnosed non-brainstem pediatric high-grade glioma in the HERBY phase II trial
| Autor: | Maura Massimino, Tim Jaspan, Gudrun Zahlmann, Monika Warmuth-Metz, Adela Cañete, Darren Hargrave, Alan Mackay, Paul S. Morgan, Marie-Cécile Le Deley, Josep Garcia, Frank Saran, Daniel Rodriguez Gutierrez, Daniel Warren, Gilles Vassal, Pascale Varlet, Raphael Rousseau, Esther Sanchez Aliaga, Jacques Grill, Chris Jones, Amedeo A. Azizi, Raphael Calmon |
|---|---|
| Přispěvatelé: | CCA - Cancer Treatment and quality of life, Radiology and nuclear medicine, CCA - Imaging and biomarkers |
| Rok vydání: | 2020 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Bevacizumab Adolescent medicine.medical_treatment Neurosurgical Procedures law.invention Histones 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Glioma Antineoplastic Combined Chemotherapy Protocols medicine Temozolomide Humans Child Survival rate Retrospective Studies business.industry Brain Neoplasms Retrospective cohort study Chemoradiotherapy medicine.disease Combined Modality Therapy Radiation therapy Clinical trial Survival Rate Oncology 030220 oncology & carcinogenesis Child Preschool Mutation Female Radiology Neoplasm Grading Neoplasm Recurrence Local business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Clinical cancer research : an official journal of the American Association for Cancer Research r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname Clinical Cancer Research, 26(8), 1856-1865. American Association for Cancer Research Inc. Gutierrez, D R, Jones, C, Varlet, P, MacKay, A, Warren, D, Warmuth-Metz, M, Aliaga, E S, Calmon, R, Hargrave, D R, Cañete, A, Massimino, M, Azizi, A A, Le Deley, M C, Saran, F, Rousseau, R F, Zahlmann, G, Garcia, J, Vassal, G, Grill, J, Morgan, P S & Jaspan, T 2020, ' Radiological evaluation of newly diagnosed non-brainstem pediatric high-grade glioma in the herby phase II trial ', Clinical Cancer Research, vol. 26, no. 8, pp. 1856-1865 . https://doi.org/10.1158/1078-0432.CCR-19-3154 |
| ISSN: | 1078-0432 |
| DOI: | 10.1158/1078-0432.CCR-19-3154 |
| Popis: | Purpose: The HERBY trial evaluated the benefit of the addition of the antiangiogenic agent Bevacizumab (BEV) to radiotherapy/temozolomide (RT/TMZ) in pediatric patients with newly diagnosed non-brainstem high-grade glioma (HGG). The work presented here aims to correlate imaging characteristics and outcome measures with pathologic and molecular data. Experimental Design: Radiological, pathologic, and molecular data were correlated with trial clinical information to retrospectively re-evaluate event-free survival (EFS) and overall survival (OS). Results: One-hundred thirteen patients were randomized to the RT/TMZ arm (n = 54) or the RT/TMZ+BEV (BEV arm; n = 59). The tumor arose in the cerebral hemispheres in 68 patients (Cerebral group) and a midline location in 45 cases (Midline group). Pathologic diagnosis was available in all cases and molecular data in 86 of 113. H3 K27M histone mutations were present in 23 of 32 Midline cases and H3 G34R/V mutations in 7 of 54 Cerebral cases. Total/near-total resection occurred in 44 of 68 (65%) Cerebral cases but in only 5 of 45 (11%) Midline cases (P < 0.05). Leptomeningeal metastases (27 cases, 13 with subependymal spread) at relapse were more frequent in Midline (17/45) than in Cerebral tumors (10/68, P < 0.05). Mean OS (14.1 months) and EFS (9.0 months) in Midline tumors were significantly lower than mean OS (20.7 months) and EFS (14.9 months) in Cerebral tumors (P < 0.05). Pseudoprogression occurred in 8 of 111 (6.2%) cases. Conclusions: This study has shown that the poor outcome of midline tumors (compared with cerebral) may be related to (1) lesser surgical resection, (2) H3 K27M histone mutations, and (3) higher leptomeningeal dissemination. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|